Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096458 · ClinicalTrials.gov registry record · Phase 1
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
A Phase 1 study of Gastroesophageal Reflux Disease and Heartburn, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02096458 is a Phase 1 study of Gastroesophageal Reflux Disease and Heartburn that has completed, run by Takeda. The registered enrollment target is 8 participants, below the 347-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02096458, a Phase 1 study of Gastroesophageal Reflux Disease and Heartburn, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
Conditions Studied
Interventions
- DRUG Dexlansoprazole
Study Locations (1)
Massachusetts
- - Woburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02096458
The ClinicalTrials.gov registry entry for NCT02096458 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (98% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 1 intervention - of which Dexlansoprazole is the first listed.
NCT02096458 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02096458 about?
NCT02096458 is a clinical study titled "Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets". The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
What is the current status of trial NCT02096458?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2014-02. Estimated completion is 2014-02.
What conditions does trial NCT02096458 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux Disease, Heartburn, Erosive Esophagitis.
What interventions are being tested in trial NCT02096458?
The interventions under investigation include: Dexlansoprazole (DRUG).
Who is sponsoring clinical trial NCT02096458?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02096458 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GCC Agonist Signal in the Small Intestine
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
COMPLETED · Phase 1
-
Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?
COMPLETED · Phase 1
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.